Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia

Psychiatry Clin Neurosci. 2007 Feb;61(1):54-8. doi: 10.1111/j.1440-1819.2007.01610.x.


Risperidone has a relatively low risk of causing obesity and diabetes mellitus and is a first-line treatment for schizophrenia. The aim of the present study was to investigate glucose and lipid metabolism, and feeding-control parameters in schizophrenia patients treated with long-term risperidone monotherapy. Fifteen patients with paranoid-type schizophrenia who had been treated with risperidone and had Global Assessment of Function (GAF) scores >70 were selected and compared with healthy volunteers (n = 25). Single assessments of psychotic symptoms, side-effects, Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) score, bodyweight, body fat percentage and blood sampling were performed. Fasting blood glucose, insulin, hemoglobin A1c, homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol, triglyceride, high density lipoprotein (HDL)-, low density lipoprotein-cholesterol, adiponectin, prolactin and feeding-control parameters (ghrelin and leptin) were analyzed. The body fat percentage (P = 0.0018), body mass index (BMI) (P = 0.0150), fasting blood glucose (P = 0.0358), triglyceride (P = 0.0377), leptin (P = 0.0243), total ghrelin (P = 0.0067), active ghrelin (P = 0.0241) and prolactin (P < 0.0001) levels of patients treated with risperidone were significantly higher than those of healthy volunteers, while the HDL-cholesterol level (P = 0.0222) was significantly lower. Although the patients had very mild psychiatric symptoms and maintained functionally high levels, the glucose and lipid parameters were significantly impaired compared to healthy volunteers. A high level of plasma ghrelin might increase appetite, leading to exacerbation of metabolic impairment.

MeSH terms

  • Adiponectin / blood
  • Adult
  • Antipsychotic Agents / adverse effects*
  • Antipsychotic Agents / therapeutic use
  • Body Composition / drug effects
  • Body Mass Index
  • Cholesterol, HDL / blood
  • Female
  • Ghrelin
  • Glucose / metabolism*
  • Humans
  • Hypertension / drug therapy
  • Hypertension / metabolism
  • Leptin / blood
  • Leptin / metabolism
  • Lipid Metabolism / drug effects*
  • Lipids / blood
  • Male
  • Middle Aged
  • Peptide Hormones / blood
  • Peptide Hormones / metabolism
  • Psychiatric Status Rating Scales
  • Risperidone / adverse effects*
  • Risperidone / therapeutic use
  • Schizophrenia / drug therapy
  • Schizophrenia / metabolism*
  • Weight Gain / drug effects


  • Adiponectin
  • Antipsychotic Agents
  • Cholesterol, HDL
  • Ghrelin
  • Leptin
  • Lipids
  • Peptide Hormones
  • Glucose
  • Risperidone